Search

Displaying results 3641 - 3650 of 5419 in total
  1. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

  2. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  3. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.

  4. Drug

    Corticosterone

    go.drugbank.com/drugs/DB04652
    Investigational

    An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

  5. Drug

    Amelubant

    go.drugbank.com/drugs/DB06248
    Investigational

  6. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

  7. Drug

    Pristinamycin

    go.drugbank.com/drugs/DB13704
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  9. Drug

    Tosufloxacin

    go.drugbank.com/drugs/DB16850
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.